GLP-1s After Surgery; Retatrutide for Pulmonary Hypertension? Vit D for Prediabetes

Incretin-based therapies after bariatric surgery were associated with clinically meaningful augmented weight loss in a dose- and timing-dependent manner, according to U.S. cohort data. (eClinicalMedicine)

A Michigan couple was charged with murder after their 7-year-old son, who weighed 255 pounds, died of dilated cardiomyopathy. (AP)

In a randomized trial, a nurse-delivered telehealth program did not substantially lower HbA1c in diabetes patients compared with a self-monitoring control program. (Annals of Internal Medicine)

Adapted American Diabetes Association youth screening guidelines showed a poor ability to predict prediabetes or early-onset type 2 diabetes before age 45, national data indicated. (JAMA Pediatrics)

STAT examined why the investigational obesity drug retatrutide might be prescribed for pulmonary hypertension as questions swirled over the mystery patient who gained access through an expanded-use program.

Many older adults are unaware that they’re about to gain access to obesity drugs through a Medicare pilot program. (CNBC)

A microsimulation modeling study using national data suggested that vitamin D supplementation for adults with prediabetes could reduce the lifetime cumulative incidence of diabetes by 8%, with a net monetary benefit of $15,483. (Lancet Regional Health Americas)

HHS proposed a further easing of the safety warnings on testosterone labeling, including eliminating a limitation on use for age-related low testosterone and removing certain prostate cancer-related warnings.

Women with a history of idiopathic premature adrenarche face an increased risk of long-term insulin resistance and hyperandrogenism, a systematic review and meta-analysis found. (Journal of Clinical Endocrinology & Metabolism)

The supply of oral progesterone appears to be shrinking with patients, clinicians, and pharmacists reporting recent intermittent shortages. (Reuters via AOL)

Corxel Pharmaceuticals said that CX11, its investigational oral small-molecule GLP-1 agent, yielded 11.5% weight loss by week 36 in a phase II trial of individuals with overweight or obesity.

The investigational GLP-1 drug bofanglutide reduced HbA1C levels at 24 weeks in a phase IIb trial of Chinese adults with type 2 diabetes, but gastrointestinal events were common. (Annals of Internal Medicine)

Long-term resistance training was associated with a substantially lower risk of type 2 diabetes in a study of over 140,000 healthcare professionals. (JAMA Network Open)

A bipartisan Senate proposal to cap insulin costs for privately insured diabetes patients at $35 per month gained some momentum. (Axios)

Please enable JavaScript to view the comments powered by Disqus.